Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Mar 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called stereotactic body radiotherapy (SBRT) on patients with advanced kidney cancer, specifically a type known as metastatic clear renal cell carcinoma. The main goal is to see if this treatment can not only shrink tumors that are directly treated with radiation but also help reduce the size of tumors that are not directly targeted—this is known as the "abscopal effect." Researchers want to find out how well SBRT works in causing these changes in other tumor areas and to monitor any potential side effects that participants may experience.

To be eligible for this study, participants need to be at least 18 years old and have been diagnosed with advanced kidney cancer that has spread (stage IV). They should have already received SBRT treatment and have measurable signs of their cancer. If you join the trial, you can expect to undergo regular assessments to track how well the treatment is working and report any side effects. This trial is currently recruiting participants and is open to all genders. It's important for potential participants to know that those with another active cancer or who cannot be regularly monitored will not be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age≥18 years at the time of signing informed consent;
• • Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
• • Previously received SBRT and concurrent PD-1 blockade treatment；
• • Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.
• Exclusion Criteria:
• • Patients who cannot be adequately followed up;
• • Has a known additional malignancy that is progressing or requires active treatment.